Samsung Bioepis Presents Phase III Data For Eylea Biosimilar

Company Also Releases New Immunogenicity Results On Byooviz Ranibizumab Biosimilar

Samsung Bioepis presented three new studies on two of its blockbuster biosimilars at the American Academy of Ophthalmology 2022 Annual Meeting, including Phase III data for its proposed aflibercept rival to Eylea.

Close-up of woman's eye framed by a digital auto-focus rectangular overlay
• Source: Shutterstock

Samsung Bioepis has unveiled Phase III interim analysis data for SB15, a proposed biosimilar for Eylea (aflibercept), in a paper presented before the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held between 30 September and 3 October.

Samsung Bioepis also took the opportunity to present two post-hoc analyses of post-Phase III, one-year results for Byooivz (ranibizumab), also...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin